Aptuit said today it has acquired Kuecept for an undisclosed price, in a deal the buyer said would help it meet customer demand for specialist drug preformulation, formulation prototyping, and ...

Dublin, Nov. 19, 2025 (GLOBE NEWSWIRE) -- The "Formulation Development Outsourcing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F" report has been added to ...

TAMPA, Fla.--(BUSINESS WIRE)--Xcelience, a leader in early drug development services, recently announced the addition of Brett F. Truitt, who will serve as Team Leader, Formulation Development in the ...

The Netherlands-based Ofichem Group signed a definitive agreement to acquire Avivia, another Netherlands-based company that specializes in formulation development. Ofichem officials say the ...

Stay ahead in the rapidly evolving LNP space with the 4 th LNP Formulation & Process Development Summit—the largest global meeting dedicated purely to LNPs. The official event guide is your must-have ...

Suzanne Jansen, MSc, PharmD, ICON, says early-phase clinical success depends on flexible, simple formulations that support wide dose ranges, matching placebos, and robust stability. Formulations are ...

Conduit Pharmaceuticals Inc. has announced a strategic services agreement with Agility Life Sciences to develop new solid oral-dosage form products for its autoimmune pipeline, intended for future ...

Coldstream Laboratories, Inc., a provider of sterile drug product development and manufacturing services, has announced that Adrian Raiche, Ph.D. has joined the company as Director of Formulation ...

In the last 10 years, there has been significant development in computer simulation of pharmaceutical materials, processes and product performance. Gradually, more mechanistically based models are ...

Clinical evaluation of several modified release once-daily formulations of danuglipron resulted in encouraging pharmacokinetic data for several candidates with one showing the most favorable profile ...

Inhibitor Therapeutics, Inc. (OTCQB: INTI) ("Inhibitor" or the "Company"), today provided an update on its ongoing pharmacokinetic (PK) clinical program supporting the treatment of surgically eligible ...